Na tej stronie
PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Lip 30, 2026
$63,46
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$61,2352tyg. minimum
$90,8752tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Przychody (TTM)
$1.01B
Twoje odznaki
Zakres 52 tyg.
$61–$91
Ocena Analityków
BUY
Cena Docelowa
$102
P/E
-117.5
ROE
20.6%
Marża Zysku Netto
-3.8%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
PTCT Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$63.46
Kapitalizacja Rynkowa (MRQ)
$5.29B
P/E (TTM)
-117.5
EPS (TTM)
$-0.54
Przychody (TTM)
$1.01B
ROE (TTM)
20.6%
D/E Dług/Kapitał (MRQ)
-3.6
Zakres 52 tyg.
$61–$91
PTCT Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O PTC Therapeutics, Inc. - Common Stock Przegląd firmy z Wikipedii
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaBiotechnology
pracownicy991
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$1.73B2016-12-31 → 2025-12-31
EPS$7.782019-12-31 → 2025-12-31
Wolny przepływ pieniężny$702M2016-12-31 → 2025-12-31
Marża netto-3.8%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | PTCT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -117.5średnia z 5 lat ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.2średnia z 5 lat ≈3.8 | ≈3.8 | 55.0 | Niedowartościowany | |
| P/B (MRQ) | -32.0średnia z 5 lat ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.2średnia z 5 lat ≈-5.5 | ≈-5.5 | · | · | |
| Cena / FCF (TTM) | -133.2średnia z 5 lat ≈-10.8 | ≈-10.8 | · | · | |
| Cena / Przepływy pieniężne (TTM) | -173.4średnia z 5 lat ≈-12.1 | ≈-12.1 | · | · | |
| EV / Przychody (TTM) | 3.6średnia z 5 lat ≈3.0 | ≈3.0 | · | · | |
| EV / FCF (TTM) | -91.9średnia z 5 lat ≈-8.4 | ≈-8.4 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | -9.3 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | PTCT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 12.5%średnia z 5 lat ≈-25.9% | ≈-25.9% | -24.1% | Najwyższa półka | |
| Marża EBITDA (TTM) | 17.9%średnia z 5 lat ≈-13.8% | ≈-13.8% | -24.1% | Najwyższa półka | |
| Marża przed opodatkowaniem (TTM) | -6.6%średnia z 5 lat ≈-43.8% | ≈-43.8% | -28.9% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | -3.8%średnia z 5 lat ≈-42.4% | ≈-42.4% | -38.1% | Najwyższa półka | |
| ROA (TTM) | -1.3%średnia z 5 lat ≈-12.6% | ≈-12.6% | -27.7% | Najwyższa półka | |
| ROE (TTM) | 20.6%średnia z 5 lat ≈-299.7% | ≈-299.7% | -40.8% | Słaby | |
| ROIC | 1044.7%średnia z 5 lat ≈267.1% | ≈267.1% | -37.7% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | PTCT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | -3.6średnia z 5 lat ≈74.5 | ≈74.5 | · | · | |
| Wskaźnik bieżący (MRQ) | 3.4średnia z 5 lat ≈2.1 | ≈2.1 | 8.3 | Niska płynność | |
| Wskaźnik Szybkości (MRQ) | 3.2średnia z 5 lat ≈2.0 | ≈2.0 | 3.2 | Zgodnie z | |
| Dług długoterminowy / Kapitał własny (MRQ) | -3.2średnia z 5 lat ≈65.1 | ≈65.1 | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | PTCT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 114.5%średnia z 5 lat ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 35.3%średnia z 5 lat ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 35.4% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | PTCT | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.8średnia z 5 lat ≈0.5 | ≈0.5 | 0.4 | Najwyższa półka | |
| Receivables Turnover (Rotacja należności) | 10.2średnia z 5 lat ≈6.8 | ≈6.8 | 9.7 | Zgodnie z | |
| Revenue / Employee (Przychody / pracownika) | ≈$1.7M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
105.2%
Następny raport
Lis 02, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 5, 2026 | $0.92 | $0.43 | 116.4% |
| 31 marca 2026 | $-0.03 | $-0.48 | 93.7% | |
| 31 grudnia 2025 | $-1.67 | $0.04 | -4460.3% | |
| 30 września 2025 | $0.20 | $-1.40 | 114.3% | |
| 30 czerwca 2025 | $-0.83 | $-1.08 | 23.3% | |
| 31 marca 2025 | $10.04 | $-0.22 | 4743.8% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $1.73B | $807M | $938M | $699M | $539M |
| Marża Operacyjna % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Zysk netto | $683M | $-363M | $-627M | $-559M | $-524M |
| Rozwodniony EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Wskaźnik bieżący | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Wskaźnik Szybkości | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $702M | $-114M | $-187M | · | $-280M |
Właściciele instytucjonalni (13F) 403 emitenci · $8.6B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
403
Wartość posiadanych akcji
$8.6B
Nowe pozycje
76
Zamknięte pozycje
43
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 76 (+7 vs poprzedni kw.) | 43 (-7 vs poprzedni kw.) | 140 (+3 vs poprzedni kw.) | 114 (+10 vs poprzedni kw.) | -1.4M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $1 139 088 671 | 13 964 554 | 13,21% | Akcje |
| VANGUARD GROUP INC | $668 691 300 | 8 803 203 | 7,75% | Akcje |
| RTW INVESTMENTS, LP | $631 875 072 | 7 746 415 | 7,33% | Akcje |
| JANUS HENDERSON GROUP PLC | $489 997 100 | 7 193 433 | 5,68% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401 986 014 | 4 928 111 | 4,66% | Akcje |
| STATE STREET CORP | $375 136 515 | 4 598 952 | 4,35% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $336 743 228 | 4 128 273 | 3,90% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $305 000 589 | 3 739 127 | 3,54% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $180 089 116 | 2 207 376 | 2,09% | Akcje |
| TORONTO DOMINION BANK | $176 668 031 | 2 165 846 | 2,05% | Akcje |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159 563 645 | 1 956 156 | 1,85% | Akcje |
| Hood River Capital Management LLC | $141 818 662 | 1 738 613 | 1,64% | Akcje |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140 519 660 | 1 722 688 | 1,63% | Akcje |
| D. E. Shaw & Co., Inc. | $126 345 323 | 1 548 919 | 1,47% | Akcje |
| TANG CAPITAL MANAGEMENT LLC | $122 355 000 | 1 500 000 | 1,42% | Akcje |
| BANK OF AMERICA CORP /DE/ | $118 462 234 | 1 452 277 | 1,37% | Akcje |
| Driehaus Capital Management LLC | $117 469 528 | 1 440 107 | 1,36% | Akcje |
| FMR LLC | $114 056 206 | 1 398 261 | 1,32% | Akcje |
| Jefferies Financial Group Inc. | $110 693 916 | 1 357 042 | 1,28% | Akcje |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94 361 749 | 1 156 819 | 1,09% | Akcje |
| Pictet Asset Management Holding SA | $93 629 635 | 1 147 844 | 1,09% | Akcje |
| MORGAN STANLEY | $90 026 886 | 1 103 675 | 1,04% | Akcje |
| ARMISTICE CAPITAL, LLC | $87 393 690 | 1 071 395 | 1,01% | Akcje |
| Blue Sparrow, LLC /DE | $85 705 599 | 1 050 700 | 0,99% | Akcje |
| FRANKLIN RESOURCES INC | $83 799 082 | 1 027 327 | 0,97% | Akcje |
| Invesco Ltd. | $76 804 761 | 941 581 | 0,89% | Akcje |
| Palo Alto Investors LP | $74 950 268 | 918 846 | 0,87% | Akcje |
| NORTHERN TRUST CORP | $71 783 966 | 880 029 | 0,83% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64 449 436 | 790 112 | 0,75% | Akcje |
| CITADEL ADVISORS LLC | $60 999 840 | 747 822 | 0,71% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $59 015 895 | 723 500 | 0,68% | Akcje |
| Boston Partners | $58 606 553 | 718 574 | 0,68% | Akcje |
| JUPITER ASSET MANAGEMENT LTD | $57 706 697 | 707 450 | 0,67% | Akcje |
| MARSHALL WACE, LLP | $57 489 476 | 704 787 | 0,67% | Akcje |
| JPMORGAN CHASE & CO | $56 073 502 | 684 042 | 0,65% | Akcje |
| ARMISTICE CAPITAL, LLC | $53 836 200 | 660 000 | 0,62% | Opcja kupna |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53 377 940 | 654 382 | 0,62% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $52 017 434 | 637 704 | 0,60% | Akcje |
| GOLDMAN SACHS GROUP INC | $50 430 408 | 618 247 | 0,58% | Akcje |
| LOOMIS SAYLES & CO L P | $48 156 807 | 590 374 | 0,56% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $47 953 943 | 587 887 | 0,56% | Akcje |
| Nuveen, LLC | $47 622 931 | 583 829 | 0,55% | Akcje |
| Bank of New York Mellon Corp | $45 145 865 | 553 462 | 0,52% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $44 181 166 | 541 635 | 0,51% | Akcje |
| VOYA INVESTMENT MANAGEMENT LLC | $43 992 251 | 539 319 | 0,51% | Akcje |
| Ensign Peak Advisors, Inc | $41 442 128 | 508 056 | 0,48% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $40 866 277 | 500 995 | 0,47% | Akcje |
| FEDERATED HERMES, INC. | $39 432 896 | 483 424 | 0,46% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36 050 432 | 441 957 | 0,42% | Akcje |
| Parkman Healthcare Partners LLC | $35 539 315 | 435 691 | 0,41% | Akcje |
Aktywiści i właściciele 5%+ 3 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 zgłoszenia | 30 stycznia 2015 | · | Pierwotne zgłoszenie | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 zgłoszenia | 12 listopada 2014 | · | Pierwotne zgłoszenie | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5 lipca 2013 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 37 insiderów · 15 dyrektorzy generalni · 20 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 4 sierpnia 2026 S | 383 868 | 0 | 13 | $-4 219 888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 31 stycznia 2023 S | 54 903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 lipca 2026 S | 83 986 | 0 | 3 | $-652 864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 27 marca 2023 S | 38 925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9 maja 2017 M | 37 850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 stycznia 2015 M | 39 247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 lutego 2020 M | 6 744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 17 sierpnia 2026 M | 105 272 | 0 | 63 | $-5 955 553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9 lipca 2026 M | 60 299 | 0 | 62 | $-25 989 291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 czerwca 2026 M | 70 199 | 0 | 5 | $-1 941 426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 czerwca 2026 S | 73 411 | 0 | 28 | $-7 477 160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 2 kwietnia 2026 S | 79 115 | 0 | 6 | $-1 081 515 |
| Mark Rothera | Chief Commercial Officer | 24 maja 2017 M | 33 739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3 stycznia 2017 A | 6 000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4 stycznia 2016 A | 3 239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Dyrektor | 30 września 2026 M | 22 500 | 0 | 2 | $-1 698 120 |
| Michael Schmertzler | Dyrektor | 17 września 2026 S | 1 296 594 | 0 | 16 | $-6 313 453 |
| Hege Elisabeth Sollie-Zetlmayer | Dyrektor | 28 lipca 2026 A | 52 526 | 0 | 0 | $0 |
| Mary L. Smith | Dyrektor | 9 lipca 2026 M | 21 813 | 0 | 2 | $-1 425 060 |
| Jessica Caroline Chutter | Dyrektor | 24 marca 2026 A | 7 333 | 0 | 0 | $0 |
| Stephanie Okey | Dyrektor | 10 marca 2026 M | 8 000 | 0 | 3 | $-1 463 076 |
| Emma Reeve | Dyrektor | 5 stycznia 2026 M | 10 666 | 0 | 15 | $-4 229 530 |
| Alethia Young | Dyrektor | 2 stycznia 2026 A | 21 067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Dyrektor | 2 stycznia 2026 A | 21 451 | 0 | 11 | $-2 912 018 |
| Jerome B Zeldis | Dyrektor | 2 stycznia 2026 A | 22 500 | 0 | 0 | $0 |
| William F. Bell Jr. | Dyrektor | 15 lutego 2024 A | 10 333 | 0 | 0 | $0 |
| Dawn Svoronos | Dyrektor | 9 czerwca 2022 S | 29 017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Dyrektor | 3 stycznia 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Dyrektor | 3 stycznia 2017 A | 2 333 333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Dyrektor | 3 stycznia 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Dyrektor | 8 czerwca 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Dyrektor | 16 marca 2015 S | 2 242 | 0 | 0 | $0 |
| Axel Bolte | Dyrektor | 25 czerwca 2013 P | 20 000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Posiadacz 10% | 17 grudnia 2013 S | 2 441 504 | 0 | 0 | $0 |
| David P Southwell | · | 2 stycznia 2026 A | 20 850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 28 kwietnia 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 25 czerwca 2013 C | 2 256 882 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 68 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,74% | 4 145 SH | 11 września 2026 | Dziennie |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2,91% | 80 293 SH | 1 października 2026 | Dziennie |
| PBE · Invesco Exchange-Traded Fund Trust | 2,44% | 159 717 SH | 1 października 2026 | Dziennie |
| MEDI · Harbor ETF Trust | 1,31% | 7 913 NS | 31 lipca 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,25% | 18 062 NS | 31 lipca 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,24% | 22 852 SH | 1 października 2026 | Dziennie |
| JSML · Janus Detroit Street Trust | 1,03% | 54 825 NS | 31 lipca 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,94% | 145 033 NS | 31 lipca 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98 733 SH | 19 sierpnia 2026 | Dziennie |
| VAMO · Cambria ETF Trust | 0,72% | 11 494 NS | 31 lipca 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,71% | 5 120 NS | 31 lipca 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,63% | 46 006 NS | 31 lipca 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,49% | 658 NS | 31 lipca 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 3 031 NS | 31 lipca 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 613 266 SH | 11 września 2026 | Dziennie |
| BRNY · EA Series Trust | 0,39% | 33 006 NS | 31 lipca 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290 018 SH | 19 sierpnia 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 5 891 SH | 1 października 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75 795 SH | 19 sierpnia 2026 | Dziennie |
| ESSC · Strategy Shares | 0,34% | 1 785 NS | 31 lipca 2026 | N-PORT |
| IWO · iShares Trust | 0,31% | 664 357 SH | 11 września 2026 | Dziennie |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 22 505 NS | 31 lipca 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 25 676 NS | 31 lipca 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,24% | 3 125 NS | 31 lipca 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477 030 SH | 19 sierpnia 2026 | Dziennie |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 19 797 NS | 31 lipca 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3 667 NS | 31 lipca 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1 099 640 SH | 19 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,18% | 2 118 779 SH | 11 września 2026 | Dziennie |
| RSSL · Global X Funds | 0,18% | 39 691 NS | 31 lipca 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,18% | 629 NS | 31 lipca 2026 | N-PORT |
| ISCG · iShares Trust | 0,16% | 23 005 SH | 11 września 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 66 833 SH | 1 października 2026 | Dziennie |
| LRGF · iShares Trust | 0,16% | 84 774 SH | 11 września 2026 | Dziennie |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35 428 SH | 19 sierpnia 2026 | Dziennie |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 51 459 NS | 31 lipca 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,14% | 18 636 NS | 31 lipca 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,13% | 5 320 SH | 1 października 2026 | Dziennie |
| FBUF · Fidelity Greenwood Street Trust | 0,12% | 413 NS | 31 lipca 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3 600 NS | 31 lipca 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 224 327 NS | 31 lipca 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 952 071 SH | 19 sierpnia 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | 0,08% | 1 902 509 SH | 19 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,08% | 211 842 SH | 19 sierpnia 2026 | Dziennie |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6 756 NS | 31 lipca 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 33 487 NS | 31 lipca 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,06% | 18 902 SH | 1 października 2026 | Dziennie |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,06% | 12 627 NS | 31 lipca 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 10 557 SH | 19 sierpnia 2026 | Dziennie |
| ESML · iShares Trust | 0,06% | 22 893 SH | 11 września 2026 | Dziennie |
| WSML · iShares Trust | 0,04% | 4 360 SH | 11 września 2026 | Dziennie |
| TILT · FlexShares Trust | 0,01% | 4 108 NS | 31 lipca 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2 636 335 SH | 19 sierpnia 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 66 405 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6 819 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18 275 SH | 19 sierpnia 2026 | Dziennie |
| ITOT · iShares Trust | 0,01% | 109 219 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,01% | 22 686 SH | 10 września 2026 | Dziennie |
| DFAC · Dimensional ETF Trust | 0,01% | 43 296 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1 090 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 284 NS | 31 lipca 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 249 NS | 31 lipca 2026 | N-PORT |
| IJR · iShares Trust | · | 5 061 986 SH | 10 września 2026 | Dziennie |
| IJT · iShares Trust | · | 784 746 SH | 9 września 2026 | Dziennie |
| IWN · iShares Trust | · | 114 658 SH | 11 września 2026 | Dziennie |
| XJR · iShares Trust | · | 11 464 SH | 31 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | · | 3 281 SH | 11 września 2026 | Dziennie |
| SMLF · iShares Trust | · | 64 380 SH | 11 września 2026 | Dziennie |
PTCT Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 21 analityków
KUP
Średni cel
$101.00
+59,2%
6 28,6%
Mocne kupno
11 52,4%
Kup
3 14,3%
Trzymaj
1 4,8%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
14 analityków · 2026-10-01Średnia cel $101.79 +60,4%
← Poniżej wszystkich celów
Aktualna cena $63.46
Niski$70.00
Średnia$101.79
Wysoki$137.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Sygnały transakcyjne Ostatnie sygnały kupna/sprzedaży z ceną wejścia i wskaźnikiem ryzyka/zysku
Obecnie brak otwartego sygnału — żadna karta nie jest wypełniona, i to jest uczciwe.
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Lip 30, 2026